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Abstract
Background and aims—Primary scleros-
ing cholangitis (PSC) is a chronic choles-
tatic liver disease of unknown aetiology.
Abnormalities in immune regulation and
genetic associations suggest that PSC is an
immune mediated disease. Several poly-
morphisms within the tumour necrosis
factor á (TNF-á) and interleukin 10 (IL-
10) promoter genes have been described
which influence expression of these cy-
tokines. This study examines the possible
association between polymorphisms at the
−308 and −627 positions in the TNF-á and
IL-10 promoter genes, respectively, and
susceptibility to PSC.
Methods—TNF-á −308 genotypes were
studied by polymerase chain reaction
(PCR) in 160 PSC patients from Norway
and the UK compared with 145 ethnically
matched controls. IL-10 −627 genotypes
were studied by PCR in 90 PSC patients
compared with 84 ethnically matched con-
trols.
Results—A total of 16% of Norwegian PSC
patients and 12% of British PSC patients
were homozygous for the TNF2 allele com-
pared with 3% and 6% of respective
controls. The TNF2 allele was present in
60% of PSC patients versus 30% of controls
(ORcombined data=3.2 (95% confidence intervals
(CI) 1.8–4.5); pcorr=10
−5). The association
between the TNF2 allele and susceptibility
to PSC was independent of the presence of
concurrent inflammatory bowel disease
(IBD) in the PSC patients; 61% of PSC
patients without IBD had TNF2 compared
with 30% of controls (ORcombined data=3.2 (95%
CI 1.2–9.0); pcorr=0.006 ). There was no
diVerence in the −627 IL-10 polymorphism
distributions between patients and controls
in either population. The increase in TNF2
allele in PSC patients only occurs in the
presence of DRB1*0301 (DR3) and B8. In
the combined population data, DRB1*0301
showed a stronger association with suscep-
tibility to PSC than both the TNF2 and
B8 alleles (ORcombined data=3.8, pcorr=10
−6 v
ORcombined data=3.2, pcorr=10
−5 v ORcombined data
=3.41, pcorr=10
−4, respectively).
Conclusions—This study identified a sig-
nificant association between possession of
the TNF2 allele, a G→A substitution at
position −308 in the TNF-á promoter, and
susceptibility to PSC. This association
was secondary to the association of PSC
with the A1-B8-DRB1*0301-DQA1*0501-
DQB1*0201 haplotype. No association was
found between the IL-10 −627 promoter
polymorphism and PSC.
(Gut 2001;49:288–294)
Keywords: primary sclerosing cholangitis; tumour
necrosis factor; interleukin 10; genetic polymorphism
Primary sclerosing cholangitis (PSC) is a
chronic cholestatic liver disease characterised by
a progressive obliterating inflammatory fibrosis
of the intrahepatic and extrahepatic bile ducts.1
Loss of functioning bile ducts leads to biliary
cirrhosis and eventually hepatic failure. Its
aetiology is unknown but the observation of
abnormal immune regulation and genetic asso-
ciations with certain HLA genes supports the
hypothesis that PSC is an immune mediated
disease. A number of studies have previously
been performed with the aim of identifying can-
didate PSC susceptibility loci, especially within
the human major histocompatibility complex on
chromosome 6. These studies have identified
two susceptibility haplotypes, A1-B8-
DRB1*0301-DQA1*0501-DQB1*0201 and
DRB1*1301-DQA1*0103-DQB1*0603.2–5 These
two haplotypes account for about 80% of PSC
patients.5 However, other candidate PSC sus-
ceptibility loci may be involved.
The genes for tumour necrosis factor á
(TNF-á) and interleukin 10 (IL-10) in particu-
lar have attracted considerable attention as pos-
sible contributors to susceptibility or resistance
to infectious, immune mediated, and auto-
immune diseases. The TNF-á gene is located in
the class III HLA region between the HLA-B
and DRB3 loci.6 A number of polymorphisms
have been described within the TNF-á pro-
moter region but the biallelic polymorphism at
position −308 is of particular interest as an
increased frequency of the rare allele TNF
−308A (termed TNF2 as opposed to the
common allele TNF-308G or TNF1) has been
reported in autoimmune disorders such as
rheumatoid arthritis, systemic lupus erythema-
tous, and coeliac disease.7–9 The functional
significance of this biallelic polymorphism re-
mains controversial; the majority of studies10–12
using reporter gene constructs have suggested
Abbreviations used in this paper: PSC, primary
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that the TNF2 allele compared with the TNF1
allele is a more powerful transcriptional activa-
tor, although this finding is not universal.13
TNF2 is part of the extended HLA-A1-B8-
DR3-DQ2 haplotype14 and individuals with this
haplotype may produce high levels of TNF-á
and be more susceptible to a spectrum of
autoimmune diseases.8
IL-10 is an important immunoregulatory
cytokine which suppresses CD4+ T helper
clones (which secrete IL-2, interferon ã, and
TNF-á ), Th1 clones, and promotes the immu-
nomodulatory T helper, Th2, clones (which
secrete IL-4, IL-10, and IL-13).15 Reciprocal
regulation mediated by secretion of cytokines
may be an important determinant of the balance
between Th1 and Th2 cells and critical for
immunoregulation. If T cells have a reduced
capacity to produce IL-10 in response to a
stimulus, Th1 responses may continue unabated
with the breakdown of peripheral tolerance and
the potential for autoimmunity to develop.
Disease association studies and studies corre-
lating IL-10 genotype with IL-10 secretion by
peripheral blood mononuclear cells provide evi-
dence for an eVect of the −627 polymorphism
on IL-10 expression. The −627*A allele is asso-
ciated with severe asthma16 and low IL-10 tissue
concentrations17 while the −627*C allele, found
in high IL-10 secretors,18 is associated with renal
disease in systemic lupus erythematosus.19 We
have previously observed decreased expression
of IL-10 mRNA in the livers of patients with
PSC suggesting that decreased secretion of this
cytokine may be implicated in the pathogenesis
of PSC.20 Given the antifibrogenic and immu-
noregulatory eVects of IL-10, we hypothesised
that polymorphism at position −627 in the
IL-10 promoter may be functional in terms of
control of cytokine secretion in vivo21 resulting in
low IL-10 production, and so could represent a
potential susceptibility locus in PSC.
In this study we sought to examine the role of
polymorphisms in both the TNF-á and IL-10
promoters (at positions −308 and −627,
respectively) in determining susceptibility to
and disease progression within PSC, by
comparing their frequencies in two distinct but
well defined Northern European PSC popula-
tions with geographically matched controls.
Patients and methods
SUBJECTS
One hundred and ten unrelated Norwegian
PSC patients attending the National Hospital,
Oslo, Norway, and 50 British PSC patients
attending the liver clinic at the Oxford RadcliVe
Hospital, Oxford, UK were included in the
study. The diagnosis of PSC was based on
accepted clinical, biochemical, radiological, and
histological criteria in the absence of evidence of
secondary cholangitis, hepatobiliary malig-
nancy, viral, metabolic, or other autoimmune
liver disease. In all cases informed consent was
obtained before inclusion in the study. Details of
the patients are given in table 1. Mean age at
presentation was 28.7 years and 47.7 years in
the Norwegian and British patients, respectively.
Over two thirds of each population was male and
the majority (∼85%) had concurrent inflamma-
tory bowel disease (IBD). IBD was diagnosed
using the characteristic endoscopic and histo-
logical criteria. In the 15% of PSC patients
without IBD included in this study, a diagnosis
of IBD was excluded by endoscopic biopsy in all
but one of the British patients and in the major-
ity of Norwegian patients.
The observation period was calculated as the
interval from the first symptom, sign, or investi-
gation consistent with a diagnosis of PSC until
the end points of death or liver transplantation
or the most recent attendance in the liver clinic.
A total of 110 Norwegian blood donors and
35 British citizens, geographically and ethni-
cally matched, were used as the control
population. None of the control subjects had
symptoms, signs, or biochemical evidence of
liver disease at recruitment.
DNA EXTRACTION
Genomic DNA was extracted from EDTA
preserved whole blood using standard tech-
niques.
GENOTYPING
Genotyping for the cytokine gene polymor-
phisms was performed by polymerase chain
reaction (PCR) amplification using sequence
specific primers and/or subsequent restriction
fragment length polymorphism. All Norwegian
and British patients and controls were included
in TNF-á −308 genotyping. SuYcient DNA for
IL-10 −627 genotyping was only available for 59
Norwegian patients, 53 Norwegian controls, 31
British patients, and 31 British controls. Each
batch of PCR reactions included a control reac-
tion to which no DNA had been added to ensure
that no contamination of samples had occurred,
and two samples of known genotype. The prod-
uct of each amplification or digestion was then
electrophoresed on a 2% agarose gel containing
ethidium bromide and visualised under
ultraviolet light.
TNF-á −308 GENOTYPING
Polymorphism at position −308 in the TNF-á
promoter was determined by PCR amplification
using sequence specific primers, as described by
Verjans and colleagues.22 Four primers were
used: the 3' primer C1 (position −144/−164:
5’-TCTCGGTTTCTTCTGGA T CG-3’)
was used in combination with either the 5'
primer C2 (position −328/−308G: 5'-
ATAGGTTTTGAGGCATGG-3'), comple-
mentary to the TNF1 allele, or the 5' primer C3
(−328/−308A: 5'-ATAGGTTTTGAGGGGC
ATGA-3') which is complementary to the
Table 1 Patient characteristics (number (%))
Norwegian
PSC patients
Norwegian
controls
British PSC
patients
British
controls
n 110 110 50 35
Male 81 (73) 77 (70) 33 (66) 24 (69)
Mean age at presentation (y) 28.7 (10–73) 47.7 (17–78)
Mean follow up period (months) 141 67
Dead 20 (18) 4 (8)
Cholangiocarcinoma 13 (12) 2 (4)
Liver transplanted 19 (17) 2 (4)
Concurrent IBD 94 (85) 43 (86)
No concurrent IBD 16 (15) 7 (14)
PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease.
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TNF2 allele. For each DNA sample, two paral-
lel reactions were performed. The primer pair
C1/C2 were used to produce specific amplifica-
tion of TNF1; C1/C3 were used to amplify the
TNF2 allele. As an internal control, primer D
(position −675 to −655: 5'-GAGTGTCCGG
GTCAGAATGA-3') was added to each reac-
tion. Amplification was carried out using the
cycling conditions previously described.23
IL-10 −627 GENOTYPING
The IL-10 −627 polymorphism was detected by
PCR-restriction fragment length polymorphism
using the primers: 5'-GGT AGG TGA GAG
TGA GGT GG-3' and 5'-GGT GAG GAG
TAG GTG AGT AGG-3' which amplify a
412 bp fragment containing the −627 polymor-
phism.24 DNA samples were amplified in 50 µl of
KCl reaction buVer (Bioline, London, UK)
containing 200 µM dNTP, 0.25 µM of each
primer, 1 µg of DNA sample, and 2 U of Taq
polymerase (Bioline) for 35 cycles at 94°C for
one minute, 50°C for one minute, and 70°C for
one minute, followed by one cycle at 70°C for 10
minutes. The PCR product (10 µl) from each
reaction was then incubated for three hours at
37°C with 3 units of Rsa I (which cleaves DNA
fragments possessing the rarer A allele but not
the more common G allele at position −627).
HLA-DR TYPING
All patients and controls were previously typed
for HLA DRB1, DQA1, and DQB1 using
diVerent genomic typing methods based on in
vitro amplification of DNA and SSO probing,
as previously described.5 Most PSC patients
and all controls were serologically typed for
HLA-B8.
STATISTICAL ANALYSIS
The frequencies of alleles in patients and con-
trols were compared using the ÷2 and Fisher’s
exact probability tests, as appropriate, with the
Epistat statistical software (EPI Info version
6.0; CDC, Atlanta, Georgia, USA). The level
of significance was set at 0.05. Bonferoni’s cor-
rection for multiple testing was applied as
follows: for comparisons of TNF-á and IL-10
genotypes, a correction factor of 8 was used
(the number of genotypes plus the two HLA
alleles DRB1*0301 and B8) and a correction
factor of 3 for stratification analysis (number of
tests performed in the analysis). Data from the
Norwegian and British populations were com-
bined using a method for analysing combined
odds ratios and ÷2 originally described by Wolf
and modified by Haldane.25 Haldanes’s analy-
sis of combined data includes both an estima-
tion for combined relative risk/odds ratio (OR)
and an estimation of the heterogeneity of the
combined data. Stratification analysis was per-
formed to determine the strongest association
between haplotypes and susceptibility to PSC
using a modification of the methods described
by Svejgaard and Ryder.26
Table 2 Distribution of the –308 tumour necrosis factor á (TNF-á) genotypes in all PSC patients and PSC patients with or without IBD versus local
controls
Norwegians British Combined data
PSC patients
All n=110
Controls
n=110 OR pcorr
PSC patients
All n=50
Controls
n=35 OR pcorr
Combined OR*
(95%CI)
Combined
(÷2 1 df)*
Probability
pcorr (÷
2 1 df)*
Heterogeneity
(÷2 2 df)*
TNF2/TNF2 18 (16) 3 (3) 6.1 0.001 6 (12) 2 (6) 2.0 0.35 3.97 (1.7–9.5) 9.53 0.016 1.54
TNF1/TNF2 45 (41) 31 (28) 1.8 28 (56) 10 (28) 3.1 2.06 (1.3–3.2) 9.17 0.02 1.14
TNF1/TNF1 47 (43) 76 (69) 0.3 16 (32) 23 (66) 0.3 0.31 (0.2–0.5) 24.16 7x 10-6 0.29
Without IBD
n=16 n=110
Without IBD
n=7 n=35
TNF2/TNF2 3 (19) 3 (3) 8.0 0.006 2 (29) 2 (6) 6.1 0.052 7.15 (2.2–23) 11.15 0.006 0.05
TNF1/TNF2 6 (38) 31 (28) 1.6 3 (42) 10 (28) 1.9 1.66 (0.8–4.5) 1.37 0.9 0.04
TNF1/TNF1 7 (44) 76 (69) 0.4 2 (29) 23 (66) 0.2 0.32 (0.1–0.5) 7.09 0.02 0.17
With IBD
n=94 n=110
With IBD
n=43 n=35
TNF2/TNF2 15 (16) 3 (3) 6.0 0.001 4 (9) 2 (6) 1.5 0.5 3.65 (1.5–9.0) 7.86 0.04 2.03
TNF1/TNF2 39 (41) 31 (28) 1.8 25 (58) 10 (28) 3.3 2.14 (1.3–3.4) 9.32 0.02 1.26
TNF1/TNF1 40 (43) 76 (69) 0.3 14 (33) 23 (66) 0.3 0.31 (0.2–0.5) 22.24 2 x 10-5 0.20
Values for patients and controls are number (%) of individuals with the given genotype.
pcorr, corrrected probability comparing the genotype distribution for PSC patients and controls.
*Method for estimating combined OR and ÷2 according to Wolf, modified by Haldane, as given in Tiwaris and Terasaki.25
PSC, primary sclerosing cholangitis; IBD, inflammatory bowel disease.
Table 3 Distribution of the –627 IL-10 genotypes in all PSC patients versus local controls
Norwegians British Combined data
PSC patients
(n=59)
Controls
(n=53) OR p
PSC patients
(n=31)
Controls
(n=31) OR p Combined OR*
Combined
(÷2 1 df)*
Probability
(÷2 1 df)*
Heterogeneity
(÷2 2 df)*
IL-10 –627
C→A
A/A 3 (5) 2 (3) 1.3 0.8 1 (3) 1 (3) 1.0 1.0 1.17 (0.3–3.9) 0.06 0.8 0.04
C/A 27 (46) 20 (37) 1.4 0.4 11 (35) 12 (39) 0.9 0.8 1.18 (0.6–2.1) 0.29 0.6 0.51
C/C 29 (49) 31 (58) 0.7 0.3 19 (62) 18 (58) 1.1 0.8 0.82 (0.5–1.5) 0.42 0.5 0.62
Values for patients and controls are number (%) of individuals with the given genotype.
*Method for estimating combined OR and ÷2 according to Wolf, modified by Haldane, as given in Tiwaris and Terasaki.25
IL-10, interleukin 10; PSC, primary sclerosing cholangitis.
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Results
−308 TNF1/TNF2 POLYMORPHISM
The frequency distribution of −308 TNF-á
polymorphism genotypes among healthy local
controls and Norwegian and British PSC
patients is shown in table 2. The phenotypic
frequency of the TNF2 allele compared with
the IL-10 −627*A allele and HLA alleles in
PSC patients and controls is given in table 4.
Tables 5 and 6 show the stratification analysis
of TNF2 in comparison with HLA-
DRB1*0301 and HLA-B8, respectively. In the
British population, the diVerence in the distri-
bution of the TNF-á −308 genotypes failed to
reach significance after correcting for multiple
testing. In the Norwegian population there was
a significant diVerence in the distribution of the
TNF-á −308 genotypes in patients versus con-
trols (OR 6.1 (95% confidence interval (CI)
2.1–18.7); p=0.001). This diVerence was due
to an excess of the TNF2 allele which was
present in 57% of the Norwegian PSC patients
versus 31% of their controls (OR 3.0 (95% CI
1.7–5.4); p=0.001). Eighteen of 110 (16%)
Norwegian PSC patients were TNF2/TNF2
homozygotes compared with only 3/110 (3%)
Norwegian controls.
In the combined data of both populations,
the TNF2 allele was present in 60% of PSC
patients versus 33% of controls (ORcombined
data=3.2 (95% CI 1.8–4.5); pcorr=10
−5 ). The
DRB1*0301 allele was present in 49% of PSC
patients versus 20% of controls (ORcombined
data=3.8 (95% CI 2.3–6.3); pcorr=10
−6 ) and the
B8 allele in 52% of PSC patients tested versus
21% of controls (ORcombined data=3.41 (95% CI
1.9–5.9); pcorr=10
−4 ). The DRB1*0301 allele
showed a stronger association with susceptibil-
ity to PSC than either TNF2 or B8.
The association between the TNF2 allele
and susceptibility to PSC was independent of
the presence of concurrent IBD. Separate
analysis of PSC patients with and without
underlying IBD is included in table 2; 61%
(14/23) of PSC patients without IBD had the
TNF2 allele compared with 30% of controls
(ORcombined data=3.2 (95% CI 1.2–9.0);
pcorr=0.006 ), a similar proportion to the whole
PSC population. Three of 16 Norwegian and
2/7 British PSC patients without underlying
IBD were TNF2/TNF2 homozygotes. In the
combined data of populations, the association
between TNF2 allele and susceptibility to PSC
appeared to be stronger in PSC patients with-
out IBD (n=23) than in those with IBD
(n=137) but this probably reflects the small
numbers in the former group.
TNF-á allele frequency was similar in males
and females and there was no diVerence in age
between patients with diVerent genotypes. The
TNF-á genotype did not significantly correlate
with disease progression, as defined by the
observation time from diagnosis to significant
clinical outcome (liver transplantation, devel-
opment of cholangiocarcinoma, death).
−627 C→A INTERLEUKIN 10 POLYMORPHISM
The genotypic distribution of the −627 IL-10
polymorphism is given in table 3. There was no
significant diVerence in the −627 IL-10Ta
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polymorphism distributions between patients
and controls in either the Norwegian or British
populations. C→A substitution at position
−627 did not appear to be associated with dis-
ease progression or severity.
DRB1*0301 AND STRATIFICATION ANALYSIS
Susceptibility to PSC is associated with two
haplotypes, A1-B8-DRB1*0301-DQA1*0501-
DQB1*0201 and DRB1*1301-DQA1*0103-
DQB1*0603.5 27 As TNF2 is known to be in
strong linkage disequilibrium with the A1-B8-
DRB1*0301-DQA1*0501-DQB1*0201 hap-
lotype, over representation of TNF2 in PSC
populations may be secondary to a primary
association of PSC with other genes carried by
this haplotype. Table 5 illustrates stratification
analysis to determine if the association between
PSC and TNF2 is a consequence of linkage
with DRB1*0301 or independent of this allele.
TNF2 was significantly increased in PSC
patients only in the presence of DRB1*0301.
This suggests that any association between
susceptibility to PSC and TNF2 may be the
result of linkage with DRB1*0301. Similarly,
table 6 illustrates that TNF2 is significantly
increased in PSC patients only in the presence
of HLA-B8.
Discussion
In the present study we have identified a
significant association between possession of
the TNF2 allele, a G→A substitution at
position −308 in the TNF-á promoter, and
susceptibility to PSC. This association was
secondary to the association of PSC with the
DRB1*0301 allele. We found no association
between the IL-10 −627 polymorphism and
PSC in either the Norwegian or British
populations.
The TNF2 allele has been shown not only to
be in strong linkage disequilibrium with the
“autoimmune” haplotype HLA-A1-B8-
DRB1*0301-DQA1*0501-DQB1*0201 but
also may be implicated in the regulation of
TNF-á transcription.14 Wilson and col-
leagues,12 using reporter gene constructs, have
shown sevenfold higher levels of transcription
from TNF2 compared with TNF1 in unstimu-
lated and PMA stimulated Raji cells. Kroeger
and colleagues10 have reported a twofold
greater level of transcription with the TNF2
compared with the TNF1 allele in a transfec-
tion assay involving luciferase as the reporter
gene. However, data relating TNF-á genotype
to TNF-á production from peripheral mono-
nuclear cells of heart transplant recipients has
not confirmed the functional significance of the
biallelic polymorphism at position −308 in the
TNF-á promoter.28 TNF-á is believed to have
an important role in the pathogenesis of severe
infectious disease, and fatal cerebral malaria is
associated with high circulating levels of this
cytokine. The TNF2 allele is independently
associated with increased susceptibility to
cerebral malaria in Gambian children.29 Stud-
ies in autoimmune diseases have been less con-
vincing although there is evidence in several
autoimmune connective tissue disorders of a
genetic contribution from the TNF locus.6 7 9
A number of studies have addressed the role
of the TNF-á polymorphism in autoimmune
liver diseases such as primary biliary cirrhosis
(PBC). Gordon and colleagues30 found that
PBC was significantly correlated with non-
carriage of the TNF2 allele, implying that this
allele confers protection against disease suscep-
tibility in PBC. Jones and colleagues31 found no
evidence for involvement of TNF-á promoter
polymorphisms in the genetic predisposition to
PBC but increased TNF1 homozygotes in
patients with advanced disease suggested that
this allele may be linked to disease progression.
Bernal and colleagues32 were the first to report
an association between the TNF2 allele and
susceptibility to PSC. The authors were unable
to determine whether the association was
primary and independent or a result of linkage
with the extended haplotype A1-B8-
DRB1*0301-DQA1*0501-DQB1*0201.
Similarly, in the present study we were
unable to show that the association between
the TNF2 allele and susceptibility to PSC was
independent of this haplotype. In particular, we
could not distinguish the association between
susceptibility to PSC with TNF2 from that
with HLA-DRB1*0301 (DR3) or HLA-B8 in
either Norwegian or British PSC patients. In
Norwegian PSC patients, DRB1*0301 ap-
peared to be more strongly associated with
PSC than TNF2 whereas in British PSC
patients the association with DRB1*0301 was
weaker and that with TNF2 and the HLA class
I allele, B8, marginally stronger (table 4). The
significance of these variations between study
populations is unclear. The TNF2 allele was
marginally increased in DRB1*0301 negative
(OR 2.0 (95% CI 1.0–4.0); p=0.2) and B8
negative (OR 2.5 (95% CI 1.0–6.1); p=0.12)
patients but this was not statistically significant
(see tables 5, 6). This observation does not
suggest that the association of TNF2 with PSC
is independent of these alleles but may be the
result of the small numbers of patients and
controls positive for TNF2 but negative for the
other alleles.
Although there was a strong association
between PSC and IBD (85% of PSC patients
Table 5 Stratification analysis of TNF2 in comparison with HLA -DRB1*0301
Phenotype Comparison with DR3−/TNF2−
DRB1*0301 TNF2 PSC patients† Controls† OR (95%CI) Probability pcorr
+ + 70 25 4.8 (2.6–8.8) 2×10-6
+ − 9 4 3.8 (1.0–14.6) 0.16
− + 27 23 2.0 (1.0–4.0) 0.2
− − 54 93
†n=160 PSC patients and 145 controls.
PSC, primary sclerosing cholangitis.
Table 6 Stratification analysis of TNF2 in comparison with HLA –B8
Phenotype Comparison with B8−/TNF2−
B8 TNF2 PSC patients Controls OR (95%CI) Probability pcorr
+ + 42 30 4.3 (2.2–8.3) 2×10-6
+ − 6 4 4.5 (1.0–15.6) 0.06
− + 14 17 2.5 (1.0–6.1) 0.12
− − 31 94
N=93 PSC patients and 145 controls.
PSC, primary sclerosing cholangitis.
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included in this study had underlying IBD), the
significant diVerence in the distribution of the
TNF −308 genotypes in PSC patients versus
controls was found in both PSC patients with
and without underlying IBD (see table 2). As
over representation of the TNF2 allele is inde-
pendent of the presence or absence of IBD, this
clearly suggests that the association of the
TNF2 allele with susceptibility to PSC is not
secondary to the powerful association between
PSC and IBD. Moreover, a number of previous
studies23 33 34 have failed to show any associ-
ation between possession of TNF polymor-
phisms and susceptibility to ulcerative colitis.
IL-10 has several important roles in the
modulation of the immune response, particu-
larly in the peripheral maintenance of self
tolerance. IL-10 produced by regulatory
CD4+ T cells or Th2 cells cross regulates
induction of proinflammatory or Th1 type
CD4+ T helper cell responses. Th1 type
responses involved in cell mediated immunity
have been implicated in the development of
autoimmunity in both experimental models
and human disease and IL-10 has been shown
to have a protective eVect against the develop-
ment of disease in animal models of auto-
immunity.35 36 Recently, we reported20 de-
creased expression of IL-10 mRNA in the
livers of patients with PSC suggesting that
decreased secretion of this cytokine and
absence of its inhibitory eVect on Th1
responses may be implicated in the pathogen-
esis of PSC. In the current study we examined
the relationship between a potentially func-
tional polymorphism at position −627 in the
IL-10 promoter gene on chromosome 1 and
susceptibility to PSC. Despite the probable
role played by IL-10 in preventing the
breakdown of self tolerance and evidence of
decreased IL-10 transcription in PSC livers, we
found no association between the IL-10 −627
promoter polymorphism and PSC.
IL-10 also has a role in fibrogenesis and
modulates matrix and metalloprotease gene
expression in fibroblasts.37 IL-10 expressed by
activated hepatic stellate cells38 downregulates
collagen gene and upregulates MMP-1 (colla-
genase I) gene expression. Possession of a
C→A substitution at −627 in the IL-10
promoter is associated with increased fibrosis
in animal models of liver injury39 and an
increased risk of fibrotic alcoholic liver dis-
ease.40 Although PSC is a fibro-obliterative dis-
ease characterised by peribiliary fibrosis and
eventually biliary cirrhosis,41 we did not find
any relationship in this study between the
IL-10 −627 polymorphism and disease severity
or progression.
A number of possibilities may explain the
findings in this study. The TNF2 allele may be
directly implicated in determining susceptibil-
ity to PSC. As the strength of the association
between TNF2 and PSC appeared to diVer in
these two northern European populations of
PSC patients, the more likely explanation is
that the association of the TNF2 allele with
susceptibility to PSC is secondary to a “true”
susceptibility gene or genes. Studies of other
HLA class III genes or other genes in linkage
with the extended haplotype A1-B8-
DRB1*0301-DQA1*0501-DQB1*0201-TNF2
may identify potential genes which may have a
“primary” pathogenetic role in PSC.
This study was supported by the European Union, contract
BMH4-CT96–0779.
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